Related Experiment Video
Updated: Jun 1, 2025
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
Elemene Injection Suppresses Pancreatic Cancer Progress through Regulating Cell Adhesion: A Research Based upon
Jiangang Zhao1,2, Fenglin Zhang1,2, Ping Li1,2
1Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Background:
This study investigates the potential effects of elemene injection on pancreatic cancer using network pharmacology and experimental validation.
Methods:
GEO database were used to acquire genes which are differentially expressed between pancreatic cancer tissue and normal tissue. The vigorous energetic ingredients were identified in research and the object genes were obtained from BATMAN-TCM. The key targets and signaling pathways of elemene injection were identified using compound- target network analysis, protein-protein interaction network analysis, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. in vitro experiments were carried out to confirm the accuracy of the network pharmacology predictions.
Results:
Two hundred and eleven target genes that may be involved in Elemene's impact on pancreatic cancer were identified. Bioinformatics analysis was conducted to determine the two active mixtures and one key target. GO and KEGG enrichment analyses indicated that elemene injection exerts therapeutic effects on pancreatic cancer, regulating the cell adhesion by ECM-receptor interaction pathway. The experiments verified that elemene injection suppressed the growth and movement of pancreatic cancer cell lines Panc02 and MiaPaca-2 and the mechanism is related to regulating ECM-receptor interaction pathway-related genes. FN1 was identified as core targets by bioinformatics analysis. The FN1 was downregulated by elemene injection and was validated by QPCR and Western Blot.
Conclusion:
The findings of the current study emphasized that elemene injection might control cell attachment, decrease metastasis, and suppresses pancreatic cancer progress. FN1 might be a therapeutic target for pancreatic cancer.
Insights
Elemene injection may inhibit pancreatic cancer progression by regulating cell adhesion and metastasis. Fibronectin 1 (FN1) was identified as a key target, showing downregulation after elemene treatment.
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Pancreatic cancer remains a significant health challenge with limited effective treatments.
- Elemene injection is being investigated for its therapeutic potential in various cancers.
Purpose of the Study:
- To investigate the molecular mechanisms of elemene injection in pancreatic cancer using network pharmacology.
- To validate the predicted targets and pathways through experimental methods.
Main Methods:
- Differential gene expression analysis using GEO database.
- Network pharmacology including compound-target and protein-protein interaction analysis.
- Gene Ontology (GO) and KEGG pathway enrichment analysis.
- In vitro validation using pancreatic cancer cell lines (Panc02, MiaPaca-2).
Main Results:
- Identified 211 target genes and key pathways involved in elemene's effect on pancreatic cancer.
- Bioinformatics analysis pinpointed Fibronectin 1 (FN1) as a core target.
- Elemene injection suppressed pancreatic cancer cell growth and migration.
- Downregulation of FN1 by elemene injection was confirmed via QPCR and Western Blot.
Conclusions:
- Elemene injection demonstrates potential in controlling pancreatic cancer cell attachment and metastasis.
- FN1 emerges as a potential therapeutic target for pancreatic cancer treatment.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
